OverviewSuggest Edit

Juvenescence is a bio-pharma development company developing therapies focused on allowing people worldwide to live longer, healthier lives. Juvenescence involved in building an ecosystem of seasoned drug developers to support scientists, universities, and institutions specializing in aging, senescence, and the diseases of aging.

HQVirgin, UT, US

Latest Updates

Employees (est.) (Jul 2019)20
Cybersecurity ratingAMore

Key People/Management at Juvenescence

David Ellam

David Ellam

Chief Financial Officer
Declan Doogan

Declan Doogan

Chief Medical Officer
David Roblin

David Roblin

Chief Operating Officer
Jim Mellon

Jim Mellon

Martin Ducker

Martin Ducker

Director of Business Development
Benjamin Swerner

Benjamin Swerner

Senior Director
Show more

Juvenescence Office Locations

Juvenescence has an office in Virgin
Virgin, UT, US (HQ)
Virgin, UT, USA
Show all (1)

Juvenescence Financials and Metrics

Summary Metrics

Founding Date


Juvenescence total Funding

$162.3 m

Juvenescence latest funding size

$100 m

Time since last funding

a year ago

Juvenescence investors

Juvenescence's latest funding round in August 2019 was reported to be $100 m. In total, Juvenescence has raised $162.3 m. Juvenescence's latest valuation is reported to be $500 m.
View all funding rounds

Juvenescence Revenue

Market valuation

Show all financial metrics

Juvenescence Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Juvenescence Online and Social Media Presence

Embed Graph

Juvenescence Blogs

AgeX Therapeutics and Juvenescence Publish Paper on Engineering Strategies for Universal Cells and Provide in Vivo Observation on Immunotolerance UniverCyte Technology Platform

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and to increase human longevity, announce the publicat…

Longevity Technology: An Interview with Dr. Greg Bailey, CEO of Juvenescence

Dr. Greg Bailey, CEO of Juvenescence gives an interview to Longevity Technology to discuss his thoughts on the longevity field and future plans for Juvenescence. In the interview, Greg discusses the origins of Juvenescence as well as his belief that the nascent longevity industry is reaching an infl…

Longevity Technology: An interview with Michael Hufford, CEO of Lygenesis

Michael Hufford, CEO of Lygenesis, gives an interview to Longevity Technology about the revolutionary Lygenesis technology and their plans for clinical development. Lygenesis’ technology will enable the use of patients lymph nodes as bioreactors to regrow functioning ectopic organs to support or rep…

Insilico Medicine secures $37M in Series B funding led by Qiming Venture Partners

Insilico Medicine, a pioneer in next-generation artificial intelligence technology for drug discovery, recently completes a USD $37 million funding round led by Qiming Venture Partners, joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital…

Juvenescence’s pipeline company Insilico Medicine uses AI to design novel molecules in 21 days

Juvenescence is impressed by Insilico Medicine’s recent article in Nature Biotech, highlighting their ability to use deep learning for de novo small-molecule design. They have developed a deep generative model, generative tensorial reinforcement learning (GENTRL) to discover potent inhibitors of dis…

AgeX Therapeutics publishes theoretical basis of human cell-age reversal in the Journal of Regenerative Medicine

Juvenescence pipeline company AgeX Therapeutics, a biotechnology company focused on therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, Ph.D., and colleagues have authored a paper in the peer-reviewed scientific journal Regenerative Medicine on the th…
Show more

Juvenescence Frequently Asked Questions

  • When was Juvenescence founded?

    Juvenescence was founded in 2017.

  • Who are Juvenescence key executives?

    Juvenescence's key executives are David Ellam, Declan Doogan and David Roblin.

  • How many employees does Juvenescence have?

    Juvenescence has 20 employees.

  • Who are Juvenescence competitors?

    Competitors of Juvenescence include GP Bullhound, Omega Healthcare Investors and Rock Health.

  • Where is Juvenescence headquarters?

    Juvenescence headquarters is located at Virgin, UT, USA, Virgin.

  • Where are Juvenescence offices?

    Juvenescence has an office in Virgin.

  • How many offices does Juvenescence have?

    Juvenescence has 1 office.